StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) KPIs and segments

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 17/3038% above fair value
$698.47+8.23 (+1.19%)

Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của IDEXX Laboratories · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của IDEXX Laboratories: 45 chỉ số vận hành, trong đó có Total Premium Instrument Placements — Worldwide, Global Active Premium Analyzer Installed Base và U.S. Companion Animal Veterinary Practice Trends, lấy từ 284 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
CAG segment revenue($M)
1,1181,0549981,0131,022920870892922889821
Water segment revenue($M)
58.650.350.554.351.045.345.250.246.743.141.8
LPD($M)
35.232.537.533.931.828.634.629.030.328.232.8
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
CAG Diagnostics Recurring Revenue($M)
975920850873878806757783808780712
Product revenue($M)
719666652656658573560568577543522
Service revenue($M)
498475438449452425394408426421380
IDEXX Vetlab Consumables($M)
430413389388375345332329325317297
Reference Laboratory Diagnostic And Consulting Services($M)
407386349363368344316328347344305
Rapid Assay Products($M)
10284.976.088.610084.077.492.810386.377.6
Veterinary Software, Services and Diagnostic Imaging Systems($M)
96.391.390.787.885.881.680.079.078.675.071.0
Recurring revenue($M)
76.373.570.671.069.065.862.964.663.159.754.6
CAG Diagnostic Capital - Instruments($M)
47.242.458.151.558.632.033.029.535.334.138.2
CAG Diagnostics Service And Accessories($M)
36.136.635.334.134.933.032.233.232.432.632.1
Systems and hardware($M)
20.017.820.116.816.915.817.114.415.415.316.5
United States($M)
773725675705718655604638660631576
Europe, the Middle East and Africa($M)
266257254245233205208199201200184
Asia Pacific($M)
10194.494.290.789.381.783.381.080.476.382.4
Canada($M)
50.840.942.041.446.737.338.336.941.036.736.9
Latin America & Caribbean($M)
25.823.223.022.320.021.021.320.2
CAG segment revenue($M)
716668604627642575519544569546
Water segment revenue($M)
43.636.533.638.135.532.132.734.832.130.5
LPD($M)
18.716.919.015.914.914.417.114.615.615.2
Product revenue($M)
514472435449452398377392397366336
Service revenue($M)
265251223234242226193204223227190
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4
Total Premium Instrument Placements — Worldwide6
5,7805,2654,6506,5675,6656,0704,1634,6254,1284,9524,7915,241
Catalyst Chemistry Analyzer Placements — Worldwide4
1,4751,3431,3601,7761,5771,4131,4691,7651,6121,8941,6682,191
Catalyst New & Competitive Placements — Worldwide2
1,1621,0081,0151,3691,2031,0911,1081,2691,1531,2951,1501,469
Catalyst Second-Analyzer Placements — Worldwide2
313334345407374322361498445560443590
Catalyst Placements — U.S.
470473481597554530530685570690570787
Catalyst Placements — International
1,0058708791,1791,0238839391,0801,0421,2041,0981,404
Premium Hematology Analyzer Placements — Worldwide4
1,4181,4021,4301,8601,6011,5251,5971,9501,6782,1982,3612,205
Premium Hematology New & Competitive — Worldwide2
1,1611,0671,1381,4501,3281,2231,2501,4661,1811,3121,2071,440
Premium Hematology Upgrades — Worldwide2
2573352922733023474978861,154
Premium Hematology Placements — U.S.
393403387500462450441518486581522694
Premium Hematology Placements — International
1,0259991,0431,3601,1391,0751,1561,4321,1921,6171,8391,511
IDEXX inVue Dx Cellular Analyzer Placements — Worldwide2
1,9041,6021,0991,9401,7532,388302
IDEXX inVue Dx Placements — U.S.
9709326381,2161,1961,829285
IDEXX inVue Dx Placements — International
93467046172455755917
SediVue Dx Urine Sediment Analyzer Placements — Worldwide2
983918761991734744795900838860762845
SediVue Dx Placements — U.S.
349343266354300270288362336361284353
SediVue Dx Placements — International
634575495637434474507538502499478492
Total Premium Instrument Placements — U.S.
2,1822,1511,7722,6672,5123,0791,5441,5751,3921,6321,3761,834
Total Premium Instrument Placements — International
3,5983,1142,8783,9003,1532,9912,6193,0502,7363,3203,4153,407
Global Active Premium Analyzer Installed Base (Thousands of Units)5
Catalyst Chemistry Analyzer Installed Base (k units)1
80.6079.8078.8077.9076.7075.8078.8074.1072.9071.7075.1069.10
Catalyst Installed Base YoY Growth(%)
5.0%5.0%5.0%5.0%5.0%6.0%7.0%8.0%9.0%10.0%
Premium Hematology Analyzer Installed Base (k units)1
58.6057.8056.9055.9054.6053.7056.9051.8050.8049.9052.8047.80
Premium Hematology Installed Base YoY Growth(%)
7.0%8.0%8.0%17.0%8.0%10.0%11.0%
SediVue Dx Analyzer Installed Base (k units)1
26.4025.7024.8024.3023.3022.7024.8021.3020.4019.6022.0018.10
SediVue Dx Installed Base YoY Growth(%)
13.0%13.0%13.0%17.0%14.0%15.0%17.0%18.0%17.0%16.0%
IDEXX inVue Dx Analyzer Installed Base (k units)
11.009.107.506.404.502.707.506.400.30
Total Global Premium Instrument Installed Base YoY Growth(%)
11.0%11.0%12.0%12.0%10.0%10.0%9.0%9.0%10.0%11.0%11.0%11.0%
U.S. Companion Animal Veterinary Practice Trends (IDEXX Practice Intelligence)5
U.S. Same-Store Practice Total Revenue YoY Growth(%)
2.4%3.5%3.9%3.0%3.3%1.6%2.1%2.0%3.0%3.4%3.3%5.2%
U.S. Same-Store Practice Total Visits YoY Growth(%)
-3.2%-2.3%-1.9%-2.6%-2.1%-3.6%-3.2%-2.7%-2.0%-2.1%-2.4%-0.7%
U.S. Same-Store Clinical Visits YoY Growth(%)2
-1.8%-1.0%-0.7%-1.6%-0.9%-2.5%-2.7%-2.7%-1.8%-1.5%-2.1%-0.1%
U.S. Non-Wellness Clinical Visits YoY Growth(%)
-0.6%0.5%0.8%0.0%0.3%-2.5%-2.4%-1.3%-0.6%-0.7%-1.8%0.2%
U.S. Wellness Clinical Visits YoY Growth(%)
-3.5%-3.3%-3.2%-4.3%-2.8%-2.4%-3.1%-5.0%-3.6%-2.6%-2.7%-0.6%
U.S. Companion Animal Diagnostic Revenue per Practice YoY Growth(%)3
5.5%6.0%6.5%6.5%6.5%5.0%4.5%4.0%3.5%5.0%5.0%7.0%
Clinical Visit Growth Contribution(%)
-2.0%-1.5%-1.0%-1.5%-1.0%-2.0%-2.5%-2.5%-2.0%-2.0%-2.5%-0.5%
Diagnostic Frequency Contribution (% of Clinical Visits Including Dx)(%)
0.5%0.5%1.0%1.0%0.5%0.5%0.5%0.0%-0.5%-0.5%0.0%0.0%
Diagnostic Utilization Contribution (Dx Revenue $ per Clinical Visit Including Dx)(%)
7.0%7.0%6.5%7.0%7.0%6.5%6.5%6.5%6.0%7.5%7.5%7.5%
IDEXX U.S. CAG Diagnostics Recurring Growth Premium vs. U.S. Clinical Visits(bps)
1,1001,1001,1001,100950800900
Companion Animal Group (CAG) Total Revenue($M)8
1,1161,1181,0549991,0131,022920871892922889821
CAG Diagnostics Recurring Revenue($M)10
967975920850873878806758783809780712
CAG Diagnostics Recurring Organic Growth(%)
11.0%10.3%11.0%10.2%10.1%7.4%4.5%6.6%9.8%
CAG Diagnostics Recurring Global Net Price Realization(%)
4.0%4.0%4.0%4.0%4.0%
CAG Diagnostics Recurring Reported Growth(%)
10.8%11.0%14.1%12.2%11.5%8.6%3.3%6.4%10.8%
CAG Diagnostics Recurring Currency Impact(%)
-0.2%0.7%3.1%1.9%1.3%1.2%-1.2%-0.2%1.0%
CAG Diagnostics Recurring Revenue — U.S.($M)2
620631595537566575537490523545523471
U.S. CAG Diagnostics Recurring Organic Growth(%)
9.6%9.7%10.7%9.5%8.3%5.6%2.7%4.1%8.9%
U.S. CAG Diagnostics Recurring Reported Growth(%)
9.6%9.7%10.7%9.5%8.3%5.6%2.7%4.1%8.9%
CAG Diagnostics Recurring Revenue — International($M)3
347344326313307303269267261264257241
International CAG Diagnostics Recurring Organic Growth(%)
13.6%11.6%11.7%11.5%13.6%10.9%8.5%11.6%11.6%
International CAG Diagnostics Recurring Reported Growth(%)
12.9%13.6%21.0%17.1%17.8%14.8%4.7%10.8%14.7%
International CAG Diagnostics Recurring Currency Impact(%)
-0.7%2.0%9.3%5.6%4.2%3.9%-3.7%-0.8%3.1%
IDEXX VetLab Consumables Revenue($M)3
443430413389388375345332329325317297
VetLab Consumables Organic Growth(%)
14.6%13.6%15.4%14.7%15.9%13.6%10.5%11.8%12.5%
VetLab Consumables Reported Growth(%)
14.3%14.7%19.7%17.2%17.8%15.3%8.8%11.6%13.9%
VetLab Consumables Currency Impact(%)
-0.3%1.1%4.2%2.5%1.9%1.7%-1.7%-0.2%1.4%
Reference Laboratory Diagnostic & Consulting Services Revenue($M)3
399407386349363368344316328347344305
Reference Laboratory Organic Growth(%)
10.2%10.3%9.7%8.9%9.4%4.8%0.9%3.8%6.9%
Reference Laboratory Reported Growth(%)
10.0%10.6%12.1%10.5%10.5%5.9%0.0%3.6%7.7%
Reference Laboratory Currency Impact(%)
-0.2%0.3%2.5%1.6%1.1%1.1%-0.8%-0.2%0.8%
Rapid Assay Products Revenue($M)3
89.110284.97688.61008477.492.810386.377.6
Rapid Assay Organic Growth(%)
0.7%1.1%-0.1%-2.5%-5.0%-3.3%-1.9%0.2%8.5%
Rapid Assay Reported Growth(%)
0.6%1.3%1.1%-1.7%-4.5%-3.0%-2.6%-0.2%9.0%
Rapid Assay Currency Impact(%)
-0.2%0.3%1.2%0.8%0.5%0.4%-0.7%-0.4%0.5%
CAG Diagnostics Services & Accessories Revenue($M)3
35.936.136.635.334.134.93332.233.232.432.632.1
CAG Services & Accessories Organic Growth(%)
5.4%2.1%7.2%7.5%1.3%6.0%3.0%0.6%17.1%
CAG Services & Accessories Reported Growth(%)
5.3%3.2%10.8%9.7%2.8%7.7%1.5%0.3%18.3%
CAG Services & Accessories Currency Impact(%)
-0.1%1.1%3.6%2.2%1.5%1.7%-1.5%-0.3%1.3%
CAG Diagnostics Capital — Instruments Revenue($M)3
51.547.242.458.151.558.6323329.535.334.138.2
CAG Capital Instruments Organic Growth(%)
0.4%-19.6%28.0%69.2%70.7%62.5%-4.6%-11.9%-2.8%
CAG Capital Instruments Reported Growth(%)
0.0%-19.5%32.7%76.1%74.3%66.0%-6.2%-13.5%-2.0%
CAG Capital Instruments Currency Impact(%)
-0.3%0.1%4.7%6.8%3.6%3.5%-1.5%-1.6%0.9%
Veterinary Software, Services & Diagnostic Imaging Systems Revenue($M)5
97.196.391.390.787.885.881.6807978.67571
Veterinary Software & Imaging Organic Growth(%)
9.9%11.8%10.9%13.0%11.0%9.2%7.5%7.2%6.1%
Veterinary Software & Imaging Reported Growth(%)
10.6%12.2%11.9%13.3%11.1%9.3%8.7%12.6%6.2%
Veterinary Software & Imaging Acquisitions Impact(%)
0.7%0.0%0.0%0.0%0.0%0.0%1.8%5.6%0.0%
Veterinary Software, Services & Imaging — Recurring Revenue($M)2
77.576.373.570.6716965.862.964.663.159.754.6
Veterinary Software Recurring Organic Growth(%)
8.2%10.2%10.7%11.9%9.7%9.1%9.0%8.5%12.0%
Veterinary Software Recurring Reported Growth(%)
9.1%10.7%11.8%12.2%9.8%9.2%10.2%15.3%12.1%
Veterinary Software, Services & Imaging — Systems & Hardware Revenue($M)2
19.72017.820.116.816.915.817.114.415.415.316.5
Veterinary Software & Imaging Hardware Organic Growth(%)
17.0%18.2%12.0%17.2%16.9%9.4%1.6%2.9%-9.5%
Veterinary Software & Imaging Hardware Reported Growth(%)
17.0%18.4%12.5%17.3%16.8%9.5%2.8%3.9%-9.6%
CAG Segment Organic Revenue Growth(%)
10.4%8.7%11.6%12.8%12.2%9.7%4.4%5.8%8.8%
CAG Segment Reported Revenue Growth(%)
10.2%9.4%14.6%14.7%13.5%10.9%3.4%6.0%9.7%
CAG Segment Currency Impact(%)
-0.2%0.6%3.0%1.9%1.3%1.2%-1.1%-0.3%0.9%
CAG Segment Revenue — U.S.($M)2
726735691643668685624574604629602550
CAG Segment Revenue — International($M)3
390383363356344338296296288294287272
Remaining Performance Obligations — Multi-Year Customer Commitment Arrangements($M)
5,3005,3004,9005,0004,7004,7004,7004,4004,2004,1003,9003,800
Remaining Performance Obligations — Reagent Rental Arrangements($M)
13911210294.775.672.369.169.172.16459.956.4
Remaining Performance Obligations — Extended Warranties (>1 Year)($M)
10.19.709.409.5099.108.808.709.109.109.509.70
Contract Assets under Customer Commitment Arrangements($M)2
349333319313289275253246247239230223
Contract Assets — Current($M)
85.782.377.775.87267.962.960.861.458.756.655.1
Contract Assets — Noncurrent($M)
263250241237217207190186186180173168
Capitalized Upfront Customer Incentives & IDEXX Points($M)2
277272265250237218198197189192168
Capitalized Customer Incentives — Current($M)
8380.176.973.67066.762.261.758.559.654.554.1
Capitalized Customer Incentives — Noncurrent($M)
194192188177167151136135130132114115
Contract Liabilities & Deferred Extended Warranty / Software PCS Revenue3
Contract Liabilities (Deferred Revenue) — Current($M)
40.236.436.335.335.736.33533.838.43838.237.2
Contract Liabilities (Deferred Revenue) — Noncurrent($M)
32.732.632.332.231.131.826.826.926.826.82828.5
Deferred Extended Warranty & Software Post-Contract Support Revenue($M)
27.627.427.327.126.326.325.825.225.825.72626
Capitalized Incremental Customer Commitment Sales Commissions($M)
20.921.121.321.421.521.522.82220.619.619.719.7
Reagent Rental & Instrument Lease Economics2
Instrument Rental & Reagent Rental Lease Revenue($M)
5.803.903.8044.803.703.303.303.503.303.805.40
Sales-Type Reagent Rental Lease Receivables($M)
20.717.517.51818.218.6181921.220.421.823.1
CAG Segment Gross Profit & Operating Income2
CAG Segment Gross Profit($M)1
701716668604628642575519545569546
CAG Segment Gross Margin(%)
62.8%64.0%63.3%62.0%62.8%62.5%61.0%61.7%61.4%
CAG Segment Operating Income($M)1
370393338329349295277242280222
CAG Segment Operating Margin(%)
33.1%35.2%32.0%32.4%34.1%32.1%31.1%26.2%31.5%
Water Microbiology Testing Segment Revenue($M)7
58.858.650.350.554.35145.345.250.246.743.141.8
Water Segment Organic Revenue Growth(%)
7.8%13.0%7.1%9.5%7.0%8.4%7.3%9.0%5.1%
Water Segment Reported Revenue Growth(%)
8.4%14.8%10.9%11.9%8.2%9.1%5.2%8.1%6.3%
Water Segment Currency Impact(%)
0.6%1.9%3.8%2.4%1.2%0.8%-2.1%-0.9%1.2%
Water Segment Revenue — U.S.($M)1
31.329.626.423.728.126.123.52226.724.522.219.9
Water U.S. Organic Revenue Growth(%)
11.5%13.5%12.3%7.4%5.2%6.7%5.9%10.6%7.2%
Water Segment Revenue — International($M)2
27.528.923.926.926.224.921.823.123.522.320.921.9
Water International Organic Revenue Growth(%)
3.9%12.4%1.9%11.5%8.9%10.2%8.9%7.4%3.2%
Water International Currency Impact(%)
1.1%3.8%7.5%4.7%2.7%1.7%-4.4%-1.7%2.3%
Water Segment Gross Profit($M)1
42.743.636.533.638.135.532.132.734.832.130.5
Water Segment Gross Margin(%)
72.6%74.4%72.7%70.1%69.6%70.8%69.3%68.6%70.8%
Water Segment Operating Income($M)1
29.630.323.726.424.620.823.620.519.417.2
Water Segment Operating Margin(%)
50.3%51.7%47.1%48.6%48.3%45.9%47.1%43.9%45.1%
Livestock, Poultry & Dairy (LPD) Segment Revenue($M)7
34.835.232.537.533.931.828.634.62930.328.232.8
LPD Segment Organic Revenue Growth(%)
3.0%9.0%7.2%4.0%14.2%2.6%4.2%7.1%-3.8%
LPD Segment Reported Revenue Growth(%)
2.6%10.8%13.6%8.5%17.1%4.8%1.4%5.4%-1.8%
LPD Segment Currency Impact(%)
-0.4%1.8%6.4%4.5%2.9%2.2%-2.8%-1.7%2.0%
LPD Segment Revenue — U.S.($M)1
7.706.606.4076.905.805.806.405.605.105.205
LPD U.S. Organic Revenue Growth(%)
11.5%14.6%10.3%9.8%23.4%12.8%12.1%29.4%8.2%
LPD Segment Revenue — International($M)2
27.228.626.130.427.12622.828.123.425.22327.8
LPD International Organic Revenue Growth(%)
0.8%7.8%6.5%2.7%12.1%0.6%2.4%3.0%-5.7%
LPD International Currency Impact(%)
-0.5%2.1%7.9%5.4%3.5%2.6%-3.4%-1.9%2.3%
LPD Segment Gross Profit($M)1
18.318.716.91915.914.914.417.114.615.615.2
LPD Segment Gross Margin(%)
52.6%53.0%52.1%47.0%47.0%50.2%50.5%51.3%54.0%
LPD Segment Operating Income($M)1
1.902.401.300.50-0.500.100.901.500.904.30
LPD Segment Operating Margin(%)
5.5%6.9%4.0%1.4%-1.6%0.4%3.1%4.9%3.1%
Other Segment Revenue (OPTI Medical Human Point-of-Care Diagnostics)($M)4
4.604.6044.104.504.304.704.104.404.203.505.80
Other Segment Organic Revenue Growth(%)
3.2%8.3%-14.0%-0.4%1.5%0.1%32.2%-28.6%-21.4%
Other Segment Reported Revenue Growth(%)
3.2%8.3%-14.0%-0.4%1.5%0.1%32.2%-28.6%-21.4%
Other Segment Gross Profit($M)1
1.901.101.801.902.202.102.202.501.10
Other Segment Gross Margin(%)
41.9%22.8%44.4%42.5%51.5%45.3%49.9%57.8%31.2%
Other Segment Operating Income($M)1
1.40-0.400.10-0.500.400.402.300.20-11.60
Other Segment Operating Margin(%)
29.8%-8.7%1.8%-11.4%10.2%9.3%52.6%5.8%-29.3%
Total Consolidated Organic Revenue Growth(%)8
10.0%9.0%11.2%12.2%12.0%9.3%4.7%5.8%7.8%
Total Consolidated Reported Revenue Growth(%)
9.9%9.7%14.3%14.3%13.3%10.6%3.6%5.8%8.8%
Total Consolidated Currency Impact(%)
-0.2%0.7%3.1%2.0%1.3%1.2%-1.2%-0.4%1.0%
Total U.S. Organic Revenue Growth(%)
8.6%7.7%10.7%11.8%10.5%8.7%3.6%4.1%7.3%
Total International Organic Revenue Growth(%)
12.4%11.2%11.9%13.0%14.6%10.5%6.8%8.8%8.7%
Non-GAAP Comparable Operating Profit($M)
398420353306355373308262304
Non-GAAP Comparable Operating Margin(%)
32.7%34.7%31.8%28.6%32.1%33.6%30.8%27.4%31.2%
Non-GAAP Comparable Gross Margin(%)
62.7%63.9%63.3%60.4%61.8%62.6%62.4%59.8%61.1%
Non-GAAP Comparable Diluted EPS($)
3.964.073.302.923.243.532.872.492.79
Full-Year Revenue Guidance Range6
Full-Year Revenue Guidance — Low($M)
4,7414,7004,6754,6324,2704,2054,0954,0553,930
Full-Year Revenue Guidance — High($M)
4,7674,7454,7604,7204,3004,2804,2104,1704,040
Full-Year Organic Revenue Growth Guidance — Low(%)
9.3%8.5%7.7%7.0%8.8%7.0%6.0%6.0%7.0%
Full-Year Organic Revenue Growth Guidance — High(%)
10.0%9.7%9.7%9.0%9.5%9.0%9.0%9.0%10.0%
Full-Year Reported Revenue Growth Guidance — Low(%)
10.1%9.1%8.6%7.6%9.6%7.7%5.0%4.0%7.5%
Full-Year Reported Revenue Growth Guidance — High(%)
10.8%10.3%10.6%9.6%10.3%9.7%8.0%7.0%10.5%
Full-Year CAG Diagnostics Recurring Growth Guidance Range4
CAG Diagnostics Recurring Organic Growth Guidance — Low(%)
10.3%9.5%8.7%8.0%7.5%5.8%5.0%5.0%7.5%
CAG Diagnostics Recurring Organic Growth Guidance — High(%)
11.0%10.7%10.7%10.0%8.2%8.0%8.0%8.0%10.5%
CAG Diagnostics Recurring Reported Growth Guidance — Low(%)
11.0%10.1%9.6%8.6%8.3%6.5%4.0%3.0%7.5%
CAG Diagnostics Recurring Reported Growth Guidance — High(%)
11.7%11.3%11.6%10.6%9.0%8.7%7.0%6.0%10.5%
Full-Year Margin, EPS, CapEx & Free Cash Flow Conversion Guidance7
Full-Year Operating Margin Guidance — Low(%)
32.1%32.3%32.1%32.0%31.6%31.3%31.1%31.0%30.2%
Full-Year Operating Margin Guidance — High(%)
32.3%32.5%32.5%32.5%31.8%31.6%31.6%31.5%30.7%
Full-Year Diluted EPS Guidance — Low($)
14.9614.6914.4514.2912.8112.4011.9311.7410.84
Full-Year Diluted EPS Guidance — High($)
15.1614.9414.9014.8013.0112.7612.4312.2411.33
Full-Year Capital Expenditures Guidance($M)
160180180180140160160160180
Full-Year Free Cash Flow Conversion Guidance (% of Net Income) — Low(%)
95.0%90.0%85.0%85.0%95.0%80.0%80.0%
Full-Year Free Cash Flow Conversion Guidance (% of Net Income) — High(%)
100.0%100.0%95.0%95.0%100.0%85.0%85.0%
Days Sales Outstanding (DSO)(ngày)
474646474745464749474646
Inventory Turns(×)
1.501.401.401.601.501.501.301.301.301.401.301.30
Inventory Breakdown by Production Stage3
Finished Goods Inventory($M)
249252250249255253256246251244259245
Raw Materials Inventory($M)
10610598.496.3103104105104107104103106
Work-in-Process Inventory($M)
35.935.534.132.63435.13531.932.43228.229
Share Repurchase Activity (Monthly & Quarterly)1
Quarterly Open-Market Shares Repurchased (Thousands)2
199.00582.00588.00356.00411.00713.00931.00564.00459.00415.00303.0090.00
Quarterly Open-Market Share Repurchase Cost($M)
11233236124224232840924922520816734.6
Quarterly Average Price Paid per Share (Open Market)($)
563571614680588459440441490501551420
Operating Lease Undiscounted Future Payments — Total($M)7
143146145148154155139140147145145141
Operating Lease Payments Due — Year 1($M)
32.831.730.332.134.232.727.826.428.426.325.224.2
Operating Lease Payments Due — Year 2($M)
28.42724.529.829.127.322.426.526.224.423.123.5
Operating Lease Payments Due — Year 3($M)
23.522.219.623.622.82116.321.120.719.618.221
Operating Lease Payments Due — Year 4($M)
15.514.712.418.618.116.912.815.114.813.913.116.1
Operating Lease Imputed Interest($M)
18.619.119.719.220.321.620.220.722.421.922.221.1
Operating Cash Outflows from Operating Leases($M)
9.208.608.408.608.708.507.606.507.706.507.207.20
ROU Assets Obtained in Exchange for New Operating Lease Liabilities($M)
4.709.105.702.706.10184.603.705.205.6011.51.20
Confirmed Supplier Finance Program Obligations Outstanding($M)
6.2076.806.207.207.208.7065.508.7010.49.10
Unrecognized Stock-Based Compensation Cost($M)
90.710512067.380.994.710863.88195.610760.2
Peer Benchmark: Zoetis Inc. (ZTS) — Consolidated Revenue($M)
2,3912,4682,2622,3732,4222,4742,1982,3172,3882,3612,1902,213
Peer Benchmark: Elanco Animal Health (ELAN) — Consolidated Revenue($M)
1,2651,3681,3711,1441,1371,2411,1931,0201,0301,1841,2051,035
Consolidated Revenue($M)8
1,2141,2171,1411,0911,1051,1109989549761,004964902
Consolidated Gross Profit($M)
764779723658683695623571596619593526
Research & Development Expense($M)
68.865.465.866.863.461.959.157.75455.452.651.8
Sales & Marketing Expense($M)
170171175167159161156150146143150142
General & Administrative Expense($M)
12311711910910698.791.610191.91579287
Consolidated Operating Income($M)
402426363316355373317262304264299245
Consolidated Net Income($M)
317338278248275294243216233203236195
GAAP Diluted Earnings per Share($)
4.014.273.473.403.632.962.802.442.81
Weighted-Average Diluted Shares(M)
79.179.380.280.781.081.983.183.484.0
Selected Balance Sheet Items10
Cash & Cash Equivalents($M)
198197201180208165164288309402397454
Accounts Receivable, Net($M)
616627604552567561528474511534507457
Total Inventories($M)
391392382378392393396382390380391380
Property, Plant & Equipment, Net($M)
732733740747739740718713718708709702
Operating Lease Right-of-Use Assets($M)
120123121123128130116116121120120116
Goodwill($M)
641411412414414415408405412408409366
Other Intangible Assets, Net($M)
11898.210511011510410711210711111584.5
Total Assets($M)
3,7073,4423,3863,3513,3873,3313,2143,2933,3513,4153,3543,260
Total Stockholders' Equity($M)
1,8691,6131,5561,6051,5611,4591,4481,5951,6181,5801,5691,485
Common Shares Outstanding(M)
78.878.979.279.78080.280.781.682.082.582.983.0
Selected Cash Flow Items5
Operating Cash Flow($M)
450347266356402186238262220248199250
Capital Expenditures (Purchases of Property & Equipment)($M)
28.924.63229.431.134.13029.328.133.330.332.6
Depreciation & Amortization($M)
40.641.137.738.736.635.834.133.734.132.229.929.7
Stock-Based Compensation Expense($M)
16.216.116.316.114.414.914.614.315.915.714.415.2
Cash Paid for Repurchases of Common Stock($M)
11234735123824033840124622121615536.9

16 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • All operational and financial figures are reported directly as published by IDEXX Laboratories, Inc., the U.S. Bureau of Labor Statistics, or peer SEC filings; the only derived cells are quarterly splits from cumulative year-to-date or full-year filings.
  • IDEXX's fiscal year ends December 31; quarterly periods Q1, Q2, Q3, and Q4 end March 31, June 30, September 30, and December 31, respectively.
  • Remaining performance obligations (RPO) under multi-year customer commitment arrangements (such as IDEXX 360) are disclosed in billions of dollars in Note 3 ($5.3B as of Q3 2026) and presented in millions ($5,300M) for unit consistency.

Không hiện vì thiếu các kỳ gần đây (11)

  • CAG Diagnostics Customer Retention Rate — Disclosed qualitatively as 'high-nineties' or as a lower bound (>97% at Investor Day), without exact point time-series values.
  • IDEXX Cancer Dx Ordering Veterinary Practices — Disclosed only as intermittent cumulative launch milestones or bounds ('nearly 5,000' in Q3 2025, 'nearly 6,000' in Q4 2025).
  • Global Commercial Reference Laboratories Count — Disclosed only as lower bounds ('more than 80' global, 'over 50' U.S., 'more than 25' international in Form 10-K).
  • SNAP Pro Analyzer Placements — Discontinued from quarterly Earnings Snapshot placement tables after Q1 2020 following transition to premium analyzer reporting.
  • IDEXX inVue Dx Installed Base YoY Growth (%) — Product launched commercially in Q1 2025; only 1 year-over-year quarterly growth observation (Q3 2026: +147%) published to date.
  • U.S. EEO-1 Consolidated Workforce Headcount (6,822 in FY2024; 6,818 in FY2023) — Excluded because the FY2025 EEO-1 report has not yet been published.
  • IDEXX Laboratorios, S.L. (Spain) Statutory Revenue & FTEs ($71.15M revenue, $2.38M pretax profit, 199 FTEs in FY2025 EU Public Country-by-Country Report) — Excluded because only a single fiscal year (FY2025) has been published under EU Directive 2021/2101.
  • Global Workforce Gender Representation (59% women overall, 50% management, 59% STEM in FY2025) — Excluded where text layout prevented complete verbatim multi-year verification across all three annual reports.
  • Investor Day Point-in-Time Survey & Operational Metrics (Brand NPS of 57, 260 reference lab pathologists, 99.99% sample processing accuracy) — Disclosed only as one-off Investor Day snapshots rather than recurring periodic series.
  • Reagent Rental & Instrument Lease Economics › Instruments Transferred from Inventory to PP&E for Operating Reagent Rentals — Excluded due to fewer than 3 consecutive recent quarters or 2 consecutive completed fiscal years.
  • Unconditional Purchase Obligations Due within 1 Year — Excluded due to fewer than 3 consecutive recent quarters or 2 consecutive completed fiscal years.

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

CAG Disaggregated Modality Revenue & Organic Growth Bridges

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của IDEXX Laboratories

See a number that looks wrong?